Amsterdam: The first oral GLP-1 pill for weight management is a step closer to European patients after the European Medicines Agency’s human medicines committee recommended Foundayo, the brand name for orforglipron, at its meeting of 12 to 15 October 2026. The Committee for Medicinal Products for Human Use backed the once-daily tablet for adults who need weight management support and for adults with type 2 diabetes. The agency published the highlights on 16 October.

A positive opinion is not yet a marketing authorisation. The European Commission now takes the final legal decision, which it normally adopts within about two months of the committee’s recommendation. Only then can the oral GLP-1 pill be sold in all 27 member states, and national authorities will still decide on pricing and reimbursement.

Foundayo belongs to the class of GLP-1 receptor agonists, which mimic a gut hormone that signals fullness and helps regulate blood sugar. Existing medicines in this class reach patients as injections, so an oral GLP-1 pill would change how doctors offer treatment, and the committee’s October meeting shows how closely regulators are watching the field. The same session recommended an extension for Kyinsu, a combination of insulin icodec and semaglutide, so the agency now has a growing set of metabolic treatments under review.

The October meeting was one of the busier ones of the year. The committee recommended six new medicines, which brings the 2026 total of positive opinions on new medicines to 72, and it issued no negative opinions at this meeting. Alongside Foundayo, the list included Rasonque for pancreatic cancer, Yuviwel for achondroplasia in children, Kizfizo for glioblastoma, and two biosimilars, Fovlussea and Neuzafy.

The committee also backed five extensions of indication, confirmed its refusal of Yartemlea after a re-examination, and recommended that the naloxone product Nyxoid become available without a prescription. Taken together, the decisions show an agency that is clearing a steady stream of products while holding firm on evidence.

For patients, the practical question is access. A tablet that needs no needle and no cold chain could widen the pool of people who consider obesity treatment, although the committee’s opinion says nothing about cost. Health ministries will weigh the price against their budgets once the Commission authorises the product, and the pace of national reimbursement decisions will decide how soon the oral GLP-1 pill reaches pharmacy shelves.

Clinicians will also watch how the product fits into care pathways. Obesity and type 2 diabetes often occur together, and one tablet that addresses both conditions could simplify prescribing for family doctors. The product information will set out the conditions for safe use once the Commission decides, and prescribers will need that detail before they offer an oral GLP-1 pill to patients.

The next signal is the Commission’s authorisation decision. Until it arrives, the committee’s recommendation of Foundayo stands as the clearest sign that Europe will soon have a daily oral GLP-1 pill on the market.